COVID-19 preclinical drug development database

Targeting intracellular vesicular trafficking using a novel V-ATPase inhibitor to ameliorate pathogenicity of SARS-CoV-2 and related viral pathogens

King's College London

Added 08/07/2020 | Updated 08/07/2020

Project Details

Type of project

  • Tier 2: testing existing molecules
  • Tier 3: discovering and categorising new molecules
  • Target identification or validation

Therapeutic target

  • Preventing infection (prophylaxis or preventing cell entry)
  • Preventing virus replication in early disease
  • Preventing cytokine release syndrome (immunomodulation or suppression)

Type of supporting technology

Phase of project

  • Lead optimisation and activity validation
  • proof of concept study to validate target of new compound

Modality (if can be disclosed)*

  • Small molecule

Molecular/cellular target (if known or can be disclosed)*

  • V-ATPase

Partner institutions/organisations

  • King's College London

Key contact

Name: Agamemnon E Grigoriadis

Email Address: agi.grigoriadis@kcl.ac.uk

Phone Number: 020-7188-1807

Key Collaborators:
Prof Agamemnon Grigoriadis Prof Paul Long Prof Michael Malim

Anticipated timeframe of future outputs

3-6 months

Further Details

Abstract or additional information (if available)*

Published outputs (if available)*

Relevant weblinks